Active substance
Quinine
- US FDA 6
- Health Canada 4
- US price lines 1
- NHS prices 3
- WHO EML 1
- Safety 4
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| QUININE SULFATE | 324MG | capsule · oral | TEVA PHARMS | Prescription | 28 Sep 2012 |
| QUININE SULFATE | 324MG | capsule · oral | LUPIN | Prescription | 24 Apr 2015 |
| QUININE SULFATE | 324MG | capsule · oral | AMNEAL PHARMS | Prescription | 15 Jul 2015 |
| QUININE SULFATE | 324MG | capsule · oral | INGENUS PHARMS LLC | Prescription | 22 Jul 2015 |
| QUALAQUIN | 324MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | capsule · oral | SUN PHARM INDUSTRIES | Discontinued | 12 Aug 2005 |
| QUININE SULFATE | 324MG | capsule · oral | AUROBINDO PHARMA USA | Discontinued | 14 Dec 2012 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| PRO-QUININE - 200 | 02311216 | 200 MG | CAPSULE · ORAL | PRO DOC LIMITEE |
| PRO-QUININE - 300 | 02311224 | 300 MG | CAPSULE · ORAL | PRO DOC LIMITEE |
| TEVA-QUININE | 00021008 | 200 MG | CAPSULE · ORAL | TEVA CANADA LIMITED |
| TEVA-QUININE | 00021016 | 300 MG | CAPSULE · ORAL | TEVA CANADA LIMITED |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | QUININE SULFATE 324 MG CAPSULE | $0.69802 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Quinine bisulfate 300mg tablets | £2.94 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Quinine sulfate 200mg tablets | £2.07 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Quinine sulfate 300mg tablets | £2.83 | 28 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 6.5.3.1. Antimalarial medicines > Medicines for curative treatment · core
Malaria due to Plasmodium falciparum
Parenteral > General injections > IV: 300 mg per mL in 2 mL ampoule (hydrochloride) solution for infusion; 60 mg per mL in 2 mL ampoule (hydrochloride) solution for infusion (EMLc)
Safety signals and safety-related labeling changes
- MHRA 24 Nov 2017 Quinine: reminder of dose-dependent QT-prolonging effects; updated medicine interactions
Quinine has dose-dependent QT-interval-prolonging effects and should be used with caution in patients with risk factors for QT prolongation or in those with atrioventricular block. - EMA PRAC 13 May 2016 PRAC signal: Increased mortality risk in heart failure patients with/without concomitant use of beta-blockers
Action for MAH: update of the product information: No - EMA PRAC 14 Jan 2016 PRAC signal: Increased mortality risk in heart failure patients with/without concomitant use of beta-blockers
Action for MAH: update of the product information: No - MHRA 11 Dec 2014 Quinine: not to be used routinely for nocturnal leg cramps
Quinine should only be considered when cramps cause regular disruption of sleep.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.